Allergan settles Restasis patent challenge after moving patents to Native American tribe

Allergan (NYSE:AGN) said yesterday that it inked a deal with InnoPharma to settle a patent challenge over Allergan’s dry eye drug, Restasis.
InnoPharma is one of four companies challenging Allergan’s patents to its eye drop product. The group also includes Mylan (NSDQ:MYL), Teva Pharmaceuticals (NYSE:TEVA) and Akorn Inc. (NSDQ:AKRX) – all of which are challenging the Restasis patents in federal court.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan settles Restasis patent challenge after moving patents to Native American tribe appeared first on MassDevice.

Source: Mass Device - October 13, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Patent Infringement Pharmaceuticals Wall Street Beat Akorn Allergan Inc. innopharma Mylan Teva Pharmaceuticals Source Type: news